Drugs.com - New Drug Approvals

Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

WILMINGTON, Del.--(BUSINESS WIRE)--May 15, 2025-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1...

May 20, 2025 - 00:10
 0
Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
WILMINGTON, Del.--(BUSINESS WIRE)--May 15, 2025-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1...
Read More

Tags:

Previous Article

Virospack introduces a syringe-style push button dropper

Next Article

Kirkland lures top Skadden corporate partner as talent war rages on

Related Posts

FDA Approves Jobevne (bevacizumab-nwgd), a Biosimilar t...

May 12, 2025  0

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)

Rinvoq (upadacitinib) Receives U.S. FDA Approval for Gi...

May 12, 2025  0

FDA Approves Opdivo (nivolumab) + Yervoy (ipilimumab) a...

May 12, 2025  0